Cytodyn Inc (CYDY)

[jbl200]

Thanks for the summary cytodyn storm. You left out one important point from the interview that I think needs to be mentioned.

The FDA has a blind spot around Leronlimab’s MoA.

The FDA’s division of anti-viral drug development is responsible for reviewing and approving Leronlimab. Leronlimab is not an anti-viral per-se. Lalezari points out that the drug should be reviewed and approved by pulmonary experts but the FDA does not have a department for pulmonary inflammation.

Referenced at 43:15 in the full interview.